Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...
(Reuters) - Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback